Patients
| Country | Value | Year |
|---|---|---|
| France | 10 | 2019 |
| Germany | 15 | 2019 |
| Italy | 15 | 2019 |
| Russia | 67 | 2019 |
| Spain | 10 | 2019 |
| UK | 13 | 2019 |
Updated
Reviewed by Vidhi Upadhyay
Europe Climate-Sensitive Disease Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Disease, Test, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$439.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $658.1 Mn | — | — |
| 2025 (base) | $695.0 Mn | +$36.9 Mn | — |
| 2026 (forecast) | $733.9 Mn | +$38.9 Mn | +5.6% |
| 2027 (forecast) | $775.0 Mn | +$41.1 Mn | +11.5% |
| 2028 (forecast) | $818.4 Mn | +$43.4 Mn | +17.8% |
| 2029 (forecast) | $864.2 Mn | +$45.8 Mn | +24.4% |
| 2030 (forecast) | $912.6 Mn | +$48.4 Mn | +31.3% |
| 2031 (forecast) | $963.7 Mn | +$51.1 Mn | +38.7% |
| 2032 (forecast) | $1.02 Bn | +$54.0 Mn | +46.4% |
| 2033 (forecast) | $1.07 Bn | +$57.0 Mn | +54.6% |
| 2034 (forecast) | $1.13 Bn | +$60.2 Mn | +63.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $695.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.13 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease and test (see all) |
| Key players | Abbott Laboratories, SD Biosensor, bioMérieux SA, Qiagen N.V., Molbio Diagnostics (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Climate-sensitive disease diagnostics detect illnesses spreading with climate change, such as dengue, malaria, cholera and heat illness.
Key segments of the climate-Sensitive Disease Diagnostics market include disease (Dengue, Malaria and Cholera) and test (Rapid Tests and Molecular Tests).
More heatwaves, air pollution, floods and the spread of climate-sensitive diseases are driving the climate-Sensitive Disease Diagnostics market. Health systems are under pressure to cut their own emissions.
Early warning systems, greener hospitals and climate-resilient supply chains give the climate-Sensitive Disease Diagnostics market strong room to grow.
Limited dedicated funding, unclear responsibility between agencies and lack of local data hold back the climate-Sensitive Disease Diagnostics market.
The climate-Sensitive Disease Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how climate-Sensitive Disease Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
What doctors and scientists are doing in Climate-Sensitive Disease Diagnostics right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| France | 10 | 2019 |
| Germany | 15 | 2019 |
| Italy | 15 | 2019 |
| Russia | 67 | 2019 |
| Spain | 10 | 2019 |
| UK | 13 | 2019 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 2 shared keywords
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe
Europe
Europe
Digital Health · Europe
Healthcare Services · Europe
Pharmaceuticals · Europe
OTC & Nutraceuticals · Europe
Pharmaceuticals · Europe
Healthcare Services · Europe